SOURCE: Skystar Bio-Pharmaceutical Company

April 17, 2007 09:30 ET

Skystar Bio-Pharmaceutical Retains CCG Elite for Investor Relations Services

XI'AN, CHINA -- (MARKET WIRE) -- April 17, 2007 -- Skystar Bio-Pharmaceutical Co., Ltd. (OTCBB: SKBI) ("Skystar"), a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign.

Skystar Bio-Pharmaceutical is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. The company currently has over 70 products in the market and over 50 new products in development. Skystar Bio-Pharmaceutical has established a strong distribution network with over 500 distribution agents throughout China and has over 200 direct customers. Its products are categorized by four segments: vaccines, veterinary medication, micro-organism, and feed additives.

"Skystar Bio-Pharmaceutical has created a leading market position in the veterinary biopharmaceutical industry. We have a proven track record for growing both revenue and net income. We intend to continue growing our business by expanding our distribution network and targeting higher margin biopharmaceuticals. We look forward to working with CCG Elite in communicating our value proposition to investors as we build our market presence and brand recognition," commented Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar Bio-Pharmaceutical.

In December 2006, Skystar Bio-Pharmaceutical expanded its production capacity with the opening of its new Good Manufacturing Practice (GMP) certified factory. The company also intends to increase its market penetration by opening four new distribution offices that will cover Zhejiang, Jiangsu, and Fujian and by implementing aggressive advertising campaigns in the local cities and villages.

"China is one of the largest livestock producers in the world and has recently experienced double-digit growth in demand for livestock. As a result, demand for veterinary medication continues to outpace supply," commented Crocker Coulson, President of CCG Elite. "Skystar Bio-Pharmaceutical is an exciting company with strong growth potential," commented Crocker Coulson, President of CCG Elite.

About CCG Elite

CCG Elite is a joint venture between Elite Communications, based in Hong Kong, and CCG, one of the leading investor relations agencies in the U.S. CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene and a direct pipeline into the leading funds and broker-dealers in the U.S. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles and offices in New York City, Irvine, CA and Hong Kong. The agency's Asia-based clients include Haier Electronics Group, Hua Han Bio-Pharmaceutical Holdings Limited, Yantai North Andre Juice Co., Sinolink Worldwide Holdings Ltd., Panva Gas Holdings Limited, Pico Far East Holdings Ltd., Kasen International Holdings Limited, Sinotronics, Good Fellow Group Limited, Century Sunshine and Citic 21CN Company Limited. CCG Elite's U.S.-based clients include TRW Automotive Holdings, Quality Systems, Accuride Corp., SI International, Lite-On Corp. and City Telecom Ltd. For further information, contact CCG Elite directly, or visit the Company's Web site at

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 70 state-of-the-art products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. Skystar recently completed construction of new state-of-the-art Bio-Pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to the company's ability to accurately complete product orders, coordinate product design with its customers, ability to expand and grow its distribution channels, political and economic factors in the People's Republic of China, the company's ability to find attractive acquisition candidates, dependence on a limited number of larger customers and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Contact
    Skystar Bio-Pharmaceutical Co., Ltd
    Scott Cramer
    Director - U.S. Representative
    Phone: 407-645-4433
    Email: Email Contact

    CCG Elite Investor Relations
    Crocker Coulson
    Email Contact

    Leslie Richardson
    Financial Writer
    Phone: 310-231-8600 x 122
    Email Contact